Podcast appearances and mentions of gregg sherman

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/candid-conversations-about-menopause-treatment-barriers-9387SummaryJoin Dr. Genevieve Neil-Perry as she moderates a dynamic panel discussion on the obstacles hindering access to quality menopause treatment. Dr. Gregg Sherman (primary care) and Dr. Nanette Santoro (OB/GYN) bring their clinical perspectives, while a patient joins and shares their firsthand experiences.This episode explores the unique challenges faced by patients and providers within the menopause care landscape. The panel delves into potential solutions, aiming to empower listeners with knowledge and strategies to overcome these barriers for improved menopause care.Learning ObjectiveIdentify patient and clinician barriers to management of menopausal symptomsThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which does not include hours of pharmacology ).For additional information about the accreditation of this program, contact NACE at info@naceonline.com.Summary of Individual DisclosuresAngela Golden has disclosed the following financial relationships:Consultant: Novo Nordisk (obesity), Lilly (obesity), Acella (thyroid), Currax (obesity), Boehringer Ingelheim (obesity), WW (obesity), Gelesis (obesity - relationship has ended)Speaker: Novo Nordisk (obesity), Lilly (obesity), Acella (thyroid), Currax (obesity)Receipt of Royalty: Springer (obesity - relationship has ended), Amazon (fiction)Guest Patient has no relevant financial relationships to disclose.Bernadette Makar has no relevant financial relationships to disclose.Gregg Sherman has no relevant financial relationships to disclose.Genevieve Neal-Perry has disclosed the following financial relationships:Scientific Advisory Board: Astellas (women's health), Natera (women's health)Review Panel: SRI (professional organization)Nanette Santoro has disclosed the following financial relationships:Consultant: Astellas Pharma, MenoGeniX, Ansh LabsAll disclosures are related to women's health.All of the relevant financial relationships listed for these individuals have been mitigated. Faculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial SupportThis educational activity is supported by an independent medical educational grant from Astellas Pharma Global Development, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/whos-at-risk-for-tardive-dyskinesia-9044 Featuring faculty Gregory Mattingly, MD, moderated by Gregg Sherman, MD. SummaryTardive Dyskinesia (TD) exerts a profound negative impact across a patient's life, including physical and cognitive domains and psychosocial functioning. This affects quality of life (QoL), increases hospitalizations and is associated with speech and eating difficulties, decreased employment, social withdrawal, stigmatization, and amplified emotional distress. In this podcast, hear from a patient who suffered with TD for years before diagnose, and discuss how to identify and support patients with TD.Learning ObjectivesUpon completion of this activity, learners should be able to:Identify the early manifestations of tardive dyskinesia (TD) in patients on antipsychotic therapyRecognize the burden associated with untreated TD and the consequences of delayed diagnosisThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).Summary of Individual DisclosuresAngela Golden has disclosed the following financial relationships:Consultant: SetPoint (obesity), WW (obesity)Advisor: Currax (obesity), Genesis (obesity), Lilly (obesity), Novo Nordisk (obesity), Acela (hypothyroidism)Speaker: Currax (obesity), Novo Nordisk (obesity)Receipt of Royalty: Amazon (fiction books), Springer (obesity book)Greg Mattingly has disclosed the following financial relationship:Consultant: AbbVie, Alkermes, Axsome, Biogen, Corium, Eisai, Ironshore, Intra-Cellular, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Redax, Roche, Sage, Sirona, Sunovion, Supernus, Takeda, TevaSpeaker: AbbVie, Alkermes, Axsome, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Sunovion, Supernus, Takeda, Tris PharmaContracted Research: AbbVie, Alkermes, Akili, Axsome, Boehringer Ingelheim, Emalex, Idorsia, Janssen, Karuna, Lumos Labs, Medgenics, Neurocrine Biosciences, NLS Pharmaceuticals, Otsuka, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, TevaAll his disclosures are related to mental healthFaculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial Support This activity is supported by an independent medical education grant from Neurocrine Biosciences, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/managing-tardive-dyskinesia-9045Featuring faculty Gregory Mattingly, MD, moderated by Gregg Sherman, MD.SummaryBesides identification of patients with Tardive Dyskinesia (TD), management options have not always provided much, if any, relief. Traditional approaches to managing TD were not only questionable, and some were potentially harmful, but the availability of newer medications has ushered in a new era in TD management. In this activity, discuss management principles and review two cases to put TD management into practice.This podcast was recorded and is being used with permission of the presenters.Learning ObjectiveUpon completion of this activity, learners should be able to:Individualize the management of TD using evidence-based strategies that target uncontrolled movementsThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).Summary of Individual DisclosuresAngela Golden has disclosed the following financial relationships:Consultant: SetPoint (obesity), WW (obesity)Advisor: Currax (obesity), Genesis (obesity), Lilly (obesity), Novo Nordisk (obesity), Acela (hypothyroidism)Speaker: Currax (obesity), Novo Nordisk (obesity)Receipt of Royalty: Amazon (fiction books), Springer (obesity book)Greg Mattingly has disclosed the following financial relationship:Consultant: AbbVie, Alkermes, Axsome, Biogen, Corium, Eisai, Ironshore, Intra-Cellular, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Redax, Roche, Sage, Sirona, Sunovion, Supernus, Takeda, TevaSpeaker: AbbVie, Alkermes, Axsome, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Sunovion, Supernus, Takeda, Tris PharmaContracted Research: AbbVie, Alkermes, Akili, Axsome, Boehringer Ingelheim, Emalex, Idorsia, Janssen, Karuna, Lumos Labs, Medgenics, Neurocrine Biosciences, NLS Pharmaceuticals, Otsuka, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, TevaAll his disclosures are related to mental healthFaculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial Support This activity is supported by an independent medical education grant from Neurocrine Biosciences, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/itching-scratching-diagnosing-prurigo-nodularis-8910Featuring faculty Shawn Kwatra, MD, moderated by Gregg Sherman, MD.SummaryPrurigo nodularis (PN) is a chronic inflammatory skin disease characterized by severe, unrelenting pruritus that is higher in intensity and associated with greater decrease in quality of life (QoL) than with other pruritic dermatoses such as atopic dermatitis and psoriasis. Patients with PN report severe disturbances in sleep, reduced participation in social activities, and absenteeism from work because of their disease.In this first of two podcast episodes, Dr. Shawn Kwatra and Dr. Gregg Sherman discuss the presentation and diagnosis of PN. Joining them is a real patient with PN to share their experience and journey.This podcast was recorded and is being used with permission of the presenters.Learning ObjectiveUpon completion of this activity, learners should be able to:Identify the clinical manifestations and differential workup associated with the accurate, timely diagnosis of prurigo nodularis (PN)This activity is accredited for CME/CE Credit.The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).Click on the link to view the summary of individual disclosures.https://docs.naceonline.com/wp-content/uploads/sites/16/2023/07/Summary-of-Individual-Disclosures.pdfDisclosure of Commercial SupportThis educational activity is supported by an independent educational grant from Sanofi and Regeneron Pharmaceuticals.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/itch-scratch-immunotherapies-for-prurigo-nodularis-8912Featuring faculty Shawn Kwatra, MD, moderated by Gregg Sherman, MDSummaryPrurigo nodularis (PN) is a chronic inflammatory skin disease characterized by severe, unrelenting pruritus that is higher in intensity and associated with greater decrease in quality of life (QoL) than with other pruritic dermatoses such as atopic dermatitis and psoriasis. Patients with PN report severe disturbances in sleep, reduced participation in social activities, and absenteeism from work because of their disease. Outcomes with traditional treatments for PN are variable and unpredictable but novel and emerging therapies, that target the underlying pathophysiology of PN, offer patients opportunities for an improved quality of life.In this second of two podcast episodes, Dr. Shawn Kwatra and Dr. Gregg Sherman discuss the pathophysiology of PN and how to incorporate recently approved and emerging therapies into the management of this condition. Joining them is a real patient with PN to share their journey and the impact of systemic therapy.This podcast was recorded and is being used with permission of the presenters.Learning ObjectivesUpon completion of this activity, learners should be able to:Describe the role of neuroimmune dysregulation in the pathophysiology of PNIndividualize therapy for patients with PN based on the best available evidence, including recent clinical trial dataThis activity is accredited for CME/CE Credit.The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).Click on the link to view the summary of individual disclosures.https://docs.naceonline.com/wp-content/uploads/sites/16/2023/07/Summary-of-Individual-Disclosures.pdfDisclosure of Commercial SupportThis educational activity is supported by an independent educational grant from Sanofi and Regeneron Pharmaceuticals.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/management-of-hyperkalemia-in-high-risk-patients-8850Featuring faculty George Bakris, MD, moderated by Gregg Sherman, MD.SummaryHyperkalemia is a common condition in certain patient populations and can increase risks for hospitalizations and mortality. The limitations of traditional treatment approaches make management of high-risk patients challenging, particularly in those with chronic kidney disease (CKD), heart failure (HF), and hypertension. However, new and emerging treatment options are available for the management of hyperkalemia and may improve outcomes in these patients.In this second of two podcast episodes, Dr. George Bakris and Dr. Gregg Sherman discuss new and emerging treatment options for the management of hyperkalemia, and how to incorporate these therapies most effectively for patients with CKD, HF, and hypertension. This podcast was recorded and is being used with the permission of the presenters.This CME/CE podcast is available for credit on myCME. Click the button on the right to listen now.Learning ObjectivesUpon completion of this activity, learners should be able to:Incorporate current and emerging therapies into the management of hyperkalemia in patients with CKD, HF, and hypertension based on recent clinical trial dataThis activity is accredited for CME/CE Credit.The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).Summary of Individual DisclosuresGeorge Bakris: has disclosed the following financial relationships:Consultant: Bayer (Diabetic Kidney Disease), KBP BioSciences (Hypertension), Ionis (Hypertension), Alnylam (Hypertension), AstraZeneca (Hyperkalemia), Novo Nordisk (Diabetic Kidney Disease), Janssen (Hypertension), inRegen (Kidney Disease)Contracted Research: KBP BioSciences (Hypertension)Angela Golden has disclosed the following financial relationships:Consultant: SetPoint (Obesity), WW (Obesity)Advisor: Currax (Obesity), Genesis (Obesity), Lilly (Obesity), Novo Nordisk (Obesity), (Obesity), Acela (Hypothyroidism)Speaker: Currax, Novo Nordisk (Obesity)Receipt of Royalty: Amazon (fiction books), Springer (obesity book)Faculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial SupportThis educational activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/limitations-of-hyperkalemia-treatment-8849Featuring faculty George Bakris, MD, moderated by Gregg Sherman, MD.SummaryHyperkalemia is a common condition in certain patient populations and can increase risks for hospitalizations and mortality, especially when potassium levels are not monitored appropriately. Furthermore, incorporating traditional treatment approaches for managing hyperkalemia have significant challenges, especially in high-risk patients.In this first of two podcast episodes, Dr. George Bakris and Dr. Gregg Sherman discuss the causes, risk factors, and consequences of hyperkalemia, as well as traditional treatment approaches and their limitations. This podcast was recorded and is being used with the permission of the presenters.This CME/CE podcast is available for credit on myCME. Click the button on the right to listen now.Learning ObjectivesUpon completion of this activity, learners should be able to:Recognize the chronic nature of hyperkalemia and its causes, risk factors, and consequencesDiscuss the management of hyperkalemia, including the challenges of dietary and traditional treatment approachesThis activity is accredited for CME/CE Credit.The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).Summary of Individual DisclosuresGeorge Bakris: has disclosed the following financial relationships:Consultant: Bayer (Diabetic Kidney Disease), KBP BioSciences (Hypertension), Ionis (Hypertension), Alnylam (Hypertension), AstraZeneca (Hyperkalemia), Novo Nordisk (Diabetic Kidney Disease), Janssen (Hypertension), inRegen (Kidney Disease)Contracted Research: KBP BioSciences (Hypertension)Angela Golden has disclosed the following financial relationships:Consultant: SetPoint (Obesity), WW (Obesity)Advisor: Currax (Obesity), Genesis (Obesity), Lilly (Obesity), Novo Nordisk (Obesity), (Obesity), Acela (Hypothyroidism)Speaker: Currax, Novo Nordisk (Obesity)Receipt of Royalty: Amazon (fiction books), Springer (obesity book)Faculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial SupportThis educational activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/residual-risk-in-chronic-kidney-disease-8865Featuring faculty Robert D. Toto, MD, moderated by Gregg Sherman, MD.SummaryChronic kidney disease (CKD) is estimated to affect 20%–40% of patients with diabetes mellitus. All-cause mortality in patients with diabetic kidney disease (DKD) is 30-fold higher than in individuals who have diabetes without CKD, and many of these deaths are due to cardiovascular disease (CVD).  Traditional steroidal MR antagonists (MRAs) are beneficial but are associated with hyperkalemia. In this first of two podcast episodes, Dr. Robert Toto and Dr. Gregg Sherman discuss the impact of MR overactivation on cardiovascular risk and CKD progression in patients with diabetes, as well as the mechanism of action and recent data regarding newer non-steroidal MRA and emerging treatment options for CKD of T2D. This podcast was recorded and is being used with permission of the presenters.Learning ObjectivesRecognize the impact of mineralocorticoid receptor (MR) overactivation on cardiovascular risk and chronic kidney disease (CKD) progression in patients with diabetesSummarize the mechanism of action, efficacy, and safety of non-steroidal MR antagonists (MRAs) and other emerging treatment options for CKD of T2DThis activity is accredited for CME/CE Credit.The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).Summary of Individual DisclosuresRobert Toto has disclosed the following financial relationships:Consultant: Amgen (Anemia in CKD), AstraZeneca (CKD), Akebia (Anemia in CKD), Bayer (CKD), Boehringer Ingelheim (CKD), Medscape (CKD anemia and hyperkalemia), Novartis (CKD), Novo Nordisk (Diabetic Kidney Disease), Otsuka (Anemia in CKD), Vifor (CKD), CinCor (CKD)Advisor – Unicycive (hyperphosphatemia in CKD)Angela Golden has disclosed the following financial relationships:Consultant: SetPoint (Obesity), WW (Obesity)Advisor: Currax (Obesity), Genesis (Obesity), Lilly (Obesity), Novo Nordisk (Obesity), (Obesity), Acela (Hypothyroidism)Speaker: Currax, Novo Nordisk (Obesity)Receipt of Royalty: Amazon (fiction books), Springer (obesity book)Faculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial SupportThis activity has been supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/the-role-of-non-steroidal-mras-in-chronic-kidney-disease-8866Featuring faculty Robert D. Toto, MD, moderated by Gregg Sherman, MD.SummaryChronic kidney disease (CKD) is estimated to affect 20%–40% of patients with diabetes mellitus. In renal disease, increased production of aldosterone and other mediators leads to overactivation of the mineralocorticoid receptor (MR). In turn, overactivation of the MR can drive progression of renal disease. Through these mechanisms, increased aldosterone production and MR overactivation contribute to adverse renal, cardiac, and vascular effects. Traditional steroidal MR antagonists (MRAs) are beneficial but are associated with hyperkalemia. However, a newer nonsteroidal MRA is available that targets MR overactivation without the risk of hyperkalemia.In this second of two podcast episodes, Dr. Robert Toto and Dr. Gregg Sherman discuss identifying appropriate candidates for nonsteroidal MRAs, as well as incorporating these therapies into the management of CKD of T2D.This podcast was recorded and is being used with permission of the presenters.Learning ObjectiveUpon completion of this activity, learners should be able to:Identify patients with CKD and T2D who are appropriate candidates for non-steroidal MRAs to manage residual riskThis activity is accredited for CME/CE Credit.The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).Summary of Individual DisclosuresRobert Toto has disclosed the following financial relationships:Consultant: Amgen (Anemia in CKD), AstraZeneca (CKD), Akebia (Anemia in CKD), Bayer (CKD), Boehringer Ingelheim (CKD), Medscape (CKD anemia and hyperkalemia), Novartis (CKD), Novo Nordisk (Diabetic Kidney Disease), Otsuka (Anemia in CKD), Vifor (CKD), CinCor (CKD)Advisor – Unicycive (hyperphosphatemia in CKD)Angela Golden has disclosed the following financial relationships:Consultant: SetPoint (Obesity), WW (Obesity)Advisor: Currax (Obesity), Genesis (Obesity), Lilly (Obesity), Novo Nordisk (Obesity), (Obesity), Acela (Hypothyroidism)Speaker: Currax, Novo Nordisk (Obesity)Receipt of Royalty: Amazon (fiction books), Springer (obesity book)Faculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial SupportThis activity has been supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/considerations-in-the-approach-to-obesity-managementFeaturing speaker Robert Kushner, MD, moderated by Gregg Sherman, MD.SummaryObesity is a chronic disease, the care of which starts in the primary care office. However, it's an intricate diagnosis that can sometimes feel too big to take on in a primary care visit. In this podcast, Dr. Robert Kushner, an obesity management specialist, and NACE Chief Medical Officer and Family Physician, Dr. Gregg Sherman, discuss the disease of obesity, its diagnosis, and aspects of management that can make addressing obesity within your patients a little less daunting.This podcast was recorded and is being used with the permission of the presenters.Learning ObjectiveUpon completion of this activity, learners should be able to:Recognize obesity as a chronic, relapsing disease with unique, distinct pathophysiology that contributes to adiposity, comorbidities, and complications.Develop individualized treatment plans for patients with obesity that incorporate evidence-based and clinical practice guidelines.This activity is accredited for CME/CE Credit.For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/considerations-in-the-approach-to-obesity-managementThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0 hours of pharmacology).The "Considerations in the Approach to Obesity Management", offered has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for up to 0.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.This activity is part of the Obesity Management in Primary Care Training and Certificate Program provided by the National Association for Continuing Education (NACE) and the American Academy of Physician Associates (AAPA) in collaboration with The Obesity Society (TOS).This educational activity is supported by an independent educational grant from Novo Nordisk Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/glp-1-ra-a-powerful-tool-for-risk-reduction-in-diabetesFeaturing speaker Javier Morales, MD, FACP, FACE, moderated by Gregg Sherman, MD.SummaryGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of therapies used for the treatment of patients with type 2 diabetes (T2D). However, the role of GLP-1 RA therapy continues to evolve and expands beyond glycemic control for these patients, and includes cardiorenal protective effects. Recently updated clinical practice guidelines now recommend treatment with GLP-1 RA therapy that has demonstrated benefit in cardiovascular risk reduction in all patients with T2D.In this podcast episode, Dr. Javier Morales and Dr. Gregg Sherman discuss strategies for selecting optimal GLP-1 RA, the early initiation of GLP-1 RA therapy in appropriate patients, and improved adherence through adverse event management.This podcast was recorded and is being used with the permission of the presenters.Learning ObjectiveUpon completion of this activity, learners should be able to:Select GLP-1 RA therapy for early use in appropriate patients with T2DM, based on current guidelines, patient characteristics, and evolving data Incorporate management strategies for the adverse gastrointestinal effects of GLP-1 RAs to improve patient adherenceThis activity is accredited for CME/CE Credit.For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/glp-1-ra-a-powerful-tool-for-risk-reduction-in-diabetesThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).This educational activity is supported by an independent educational grant from Novo Nordisk Inc.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/the-unmet-needs-of-iron-deficiency-screening-diagnosisFeaturing speakers Lee P. Shulman, MD, and Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, moderated by Gregg Sherman, MD.SummaryDo you consider iron deficiency anemia (IDA) as much as you should in at-risk patients? A third of the US population will experience IDA in their lifetime, whether due to blood loss or nutritional deficiency. How do you determine which third of your patients have or are at risk for this condition? In this, the first of a 2-podcast series on IDA, experts in primary care and OB/GYN discuss with our primary care moderator the identification of patients who need screening for anemia and iron deficiency and how to screen and diagnose those patients. Hemoglobin, transferrin saturation, serum iron, ferritin! With so many options, how does a provider thoughtfully approach the workup of IDA? Tune in, and find out.This podcast was recorded and is being used with the permission of the presenters.Learning ObjectiveUpon completion of this activity, learners should be able to:Recognize patients at risk for iron deficiency anemiaAccurately assess iron stores in patients with anemia and those on iron replacement therapyThis activity is accredited for CME/CE Credit.For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/the-unmet-needs-of-iron-deficiency-screening-diagnosisThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).This activity is supported by an educational grant from Shield Therapeutics.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/treating-iron-deficiency-anemia-what-you-need-to-know-nowFeaturing speakers Lee P. Shulman, MD, and Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, moderated by Gregg Sherman, MD.SummaryAs prevalent as IDA is in the population, how do you treat their anemia and replete iron stores? Sulfate, gluconate, or maltol? This discussion, between two respective experts in primary care and OB/GYN and our primary care moderator, continues and concludes our 2-part podcast series to answer that question. Oral and parenteral iron repletion, managing and mitigating side effects, and monitoring efficacy of treatment round out the discussion on the management of IDA.This podcast was recorded and is being used with the permission of the presenters.Learning ObjectiveUpon completion of this activity, learners should be able to:Utilize an evidence-based, patient approach to management of iron deficiency that maximizes adherence to treatmentAccurately assess iron stores in patients with anemia and those on iron replacement therapy.This activity is accredited for CME/CE Credit.For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/treating-iron-deficiency-anemia-what-you-need-to-know-nowThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).This activity is supported by an educational grant from Shield Therapeutics.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/putting-evolving-data-into-practice-in-copd-careFeaturing speaker Fernando Martinez, MD, MS, moderated by Gregg Sherman, MDSummaryCOPD is a common disease that is characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities. Approximately 16 million people in the United States are diagnosed with COPD, and many more remain undiagnosed. The disease is the fourth leading cause of death in the United States. COPD should be considered in patients who have dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease. Evolving case-finding approaches seek to identify undiagnosed patients who would benefit from treatment. Once diagnosed with diagnostic classification guides personalization of COPD therapy, taking into account exacerbations and comorbidities, as well. In this activity, Dr. Martinez will discuss with the moderator case-finding, diagnosis, and approaches to treatment, giving time to answer common questions on these topics.This podcast was recorded and is being used with the permission of the presenters.Learning ObjectivesUpon completion of this activity, learners should be able to:Utilize evolving approaches to case-finding and spirometry to ensure early diagnosis of COPDEmploy current and emerging therapeutic strategies to ensure guideline-based management of COPDThis activity is accredited for CME/CE Credit.For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/putting-evolving-data-into-practice-in-copd-careThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).This activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Optimizing Asthma Outcomes: Difficult-to-Treat and Severe Asthma in Primary Care PodcastFeaturing Neil Skolnik, MD as faculty, moderated by Gregg Sherman, MD.SummaryIn this episode, Dr. Skolnick and Dr. Sherman address recent advances in asthma treatment which allow for greater individualization of therapy, particularly for patients with difficult-to-treat and severe asthma.  Available therapies are highly effective for asthma management, yet for a number of reasons,  in practice, asthma is often not optimally controlled.  This podcast will help clinicians recognize how to identify asthma phenotypes to guide therapeutic decision making, incorporate the most recent GINA guidelines into practice, and identify patients with moderate to severe asthma that require more aggressive care, including biologic therapy.This podcast was recorded and is being used with the permission of the presenters.Learning ObjectivesUpon completion of this activity, learners should be able to:Recognize different phenotypes, asthma severity, and modifiable and non-modifiable factors that contribute to poor asthma control in order to make personalized treatment decisionsSelect guideline-directed therapy and patient management strategies, including referral when appropriate, based on individualized characteristics in patients with difficult-to-treat or severe asthmaThis activity is accredited for CME/CE credit.  For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Optimizing Asthma Outcomes: Difficult-to-Treat and Severe Asthma in Primary Care PodcastThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Migraine Management: Are You Up To Speed? PodcastFeaturing Alan M. Rapoport, MD as faculty, moderated by Gregg Sherman, MD.SummaryRecent advances in the understanding and treatment of migraine offer the opportunity to individualize the care of patients with this disorder. Multiple new treatment options are available, marking a new era in migraine management. As older therapies for migraine are associated with adverse effects that may be intolerable, PCPs need to be familiar with clinical trial data for newer drug therapies that are both effective and well tolerated, in order to be able to make appropriate management decisions. This course will review the use of acute care therapies to manage migraine, based on therapies' mechanisms of action, safety, and efficacy data, as well as the patient's preferences; and preventive therapy to manage patients with migraine, based on therapies' mechanisms of action, clinical trial data, and side-effect profile, as well as the patient's preferences.This podcast was recorded and is being used with the permission of the presenters.Learning ObjectivesUpon completion of this activity, learners should be able to:Individualize the use of acute care therapies to manage migraine, based on therapies' mechanisms of action, safety, and efficacy data, as well as the patient's preferences.Utilize preventive therapy to manage patients with migraine, based on therapies' mechanisms of action, clinical trial data, and side-effect profile, as well as the patient's preferences.This activity is accredited for CME/CE credit. For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Migraine Management: Are You Up To Speed? PodcastAccreditation Statement– CME ProviderIn support of improving patient care, Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Credit Designation StatementAlbert Einstein College of Medicine-Montefiore Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.Accreditation Statement – AANP ProviderNational Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).This activity is supported by an educational grant from Biohaven Pharmaceuticals.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Effective Management of Pulmonary Arterial Hypertension: Primary Care's Primary Role PodcastFeaturing Stacy A. Mandras, MD, FACC as faculty, moderated by Gregg Sherman, MD.Pulmonary arterial hypertension (PAH) is a progressive and life-threatening condition characterized by increased pulmonary vascular resistance which can lead to right heart failure and premature death. As first-line healthcare providers, primary care clinicians play a key role in the early recognition of PAH, and referral of patients to specialists to confirm the diagnosis. Thereafter, primary care providers (PCPs) also play a crucial role in the ongoing monitoring and management of PAH patients. However, in practice, early recognition and management of PAH is challenging as PAH does not become clinically manifest until pulmonary vascular disease is advanced. This activity will focus on PAH diagnostic tools, monitoring, and management strategies to optimize care and patient outcomes. This podcast was recorded and is being used with the permission of the presenters.Learning ObjectivesUpon completion of this activity, learners should be able to:Diagnose PAH using updated definitions and diagnostic toolsPromote patient adherence through the management of adverse events that are associated with PAH therapiesThis activity is accredited for CME/CE credit.  For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Effective Management of Pulmonary Arterial Hypertension: Primary Care's Primary Role PodcastThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).This educational activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:A Guideline Approach to Managing Diabetes: Improving Outcomes with GLP-1 RA Therapy PodcastFeaturing James R. Gavin III, MD, PhD as faculty, moderated by Gregg Sherman, MD.Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a relatively newer drug group for type 2 diabetes (T2DM) management, which demonstrate excellent efficacy for glycemic control. They reduce HbA1c and have low glycemic variability and a low risk of hypoglycemia. GLP-1 RAs also delay gastric emptying, reduce appetite, and promote weight loss. Subsequently, GLP-1 RAs are the preferred agents to treat T2DM patients in whom there is a compelling need to minimize hypoglycemia or to minimize weight gain/promote weight loss. Initiating therapy with a GLP-1 RA ahead of insulin may be preferred for patients who need an injectable's greater glucose-lowering effect. Recent cardiovascular outcome trials (CVOTs) have also demonstrated the cardiorenal benefits of some GLP-1 RAs, and these agents are indicated for T2DM patients who have atherosclerotic cardiovascular disease (ASCVD) or indicators of high risk, established kidney disease or heart failure. This course will address diagnosis, treatment, and clinician-patient communication strategies to optimize patient care.This podcast was recorded and is being used with the permission of the presenters.Learning ObjectivesUpon completion of this activity, learners should be able to:Describe the glycemic and non-glycemic benefits of various GLP-1 receptor agonists that are currently available as well as the patient profile for which GLP-1 receptor agonists produced the best outcomesOptimize treatment selection of GLP-1 receptor agonist therapy for patients with type 2 diabetes (T2D) based on current guidelines, patient characteristics, and evolving outcome dataUtilize effective communication to optimize shared decision-making and involve patients in discussions concerning GLP-1 receptor agonist therapy in order to decrease barriers to care, improving adherence, decrease cardiovascular risk, and optimize patient outcomesThis activity is accredited for CME/CE credit.  For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:A Guideline Approach to Managing Diabetes: Improving Outcomes with GLP-1 RA Therapy PodcastThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).This educational activity is supported by an educational grant from Novo Nordisk, Inc.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/using-natriuretic-peptides-effectively-in-heart-failure-podcast?client=  Featuring James L. Januzzi, MD, FACC, FESC as faculty, moderated by Gregg Sherman, MD.This course will review natriuretic peptide (NP) testing, based on guideline recommendations, to diagnose heart failure (HF), including patients in high-risk populations, such as those with diabetes mellitus or hypertension. In addition, the course will cover NP testing for prognostication in patients with established HF, or at risk for HF, including those with existing comorbidities such as diabetes mellitus or hypertension, as part of their overall disease monitoring and pharmacotherapeutic management.  Originally limited to the diagnosis of acute heart failure (HF) in the emergency room, natriuretic peptides (NPs) are now considered valuable markers that can be useful in the screening, diagnosis, prognostication, and monitoring of patients with HF. NP testing can be used to rule out HF in patients presenting with acute or chronic dyspnea, for prognostication in patients diagnosed with HF, and to guide therapy for chronic HF patients. As primary care clinicians play a crucial role in the early recognition and ongoing monitoring of patients with HF, it is important that they be familiar with the role of NPs in HF and with current recommendations regarding NP testing for screening, diagnosis, prognostication, and monitoring in HF in order to improve patient care and outcomes.This activity is accredited for CME/CE credit.  For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/using-natriuretic-peptides-effectively-in-heart-failure-podcast?client=The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.5 contact hour (which includes 0 hours of pharmacology).This educational activity is supported by an educational grant from Roche Diagnostics Corporation.

In this podcast, Dr. Adam Friedman and Dr. Gregg Sherman provide an update on appropriately diagnosing psoriasis, recognizing comorbidities, implementing appropriate therapeutic strategies, and the impact of COVID-19 with regards to treatment.For CME programs on a variety of topics, visit the NACE website at https://www.naceonline.com/FacultyAdam Friedman, MD, FAADProfessor and Interim Chair of DermatologyResidency Program DirectorDirector of Translational ResearchDirector of Supportive OncodermatologyDepartment of DermatologyGeorge Washington School of Medicine and Health SciencesWashington, DCThis podcast was developed by Albert Einstein College of Medicine-Montefiore Medical Center in collaboration with NACE.This educational activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.This activity is not certified for CME/CE credit.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/managing-heart-failure-in-primary-care-podcastFeaturing Alanna Morris, MD, MSc, FHFSA, FACC, FAHA as faculty, moderated by Gregg Sherman, MD.This course will review evidence-based guidelines for early recognition and diagnosis of Heart Failure (HF), development of patient care plans that consider the latest guidelines and clinical data, as well as patient characteristics,  and the benefits of a multi-disciplinary team and shared-decision making approach to improve patient outcomes. Heart failure (HF) is a growing problem that affects an estimated 6.2 million adults in the United States. The availability of effective medical therapies for HF, including newer agents, offers the prospect of improved outcomes. However, HF remains underdiagnosed, and the assessment and management of HF patients may not align with evidence-based guidelines. Primary care providers (PCPs) are frequently the first line of care for patients with HF and are frequently responsible for making timely and accurate diagnoses, initiating therapy, and managing comorbidities. This activity is certified for CME/CE credit.For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.naceonline.com/courses/managing-heart-failure-in-primary-care-podcastAssociation of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Association of Black Cardiologists, Inc. designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 21222. This activity is approved for 0.5 contact hours (which includes 0 hours of pharmacology).This educational activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Dr. Daniel Soffer and host Dr.  Gregg Sherman discuss the  impact of statin intolerance, emerging non-statin therapies, and strategies to reduce cardiovascular risk in statin intolerant patients.Click here to watch the  one hour webcast on this topic and Earn CME/CE credit!GuestDaniel Soffer, MD, FNLAUniversity of Pennsylvania Health SystemInternal Medicine/Clinical LipidologyPhiladelphia, PAHostGregg Sherman, MDChief Medical Officer/Course DirectorNational Association for Continuing EducationPlantation, FLThis activity is not certified for CME/CE credit.This educational activity is supported in part by an educational grant from Esperion Therapeutics, Inc.

In this episode, host Dr. Gregg Sherman and NACE expert faculty member, Lucia M. Novak, MSN, ANP-BC. BC-ADM, discuss Optimizing Outcomes in Diabetes With GLP-1 Therapy. Dr. Sherman and Ms. Novak discuss the glycemic and cardiorenal effects of GLP-1 RAs, the differences between injectable and oral GLP-1 RA formulations, and strategies for integrating GLP-1 RA therapy into earlier therapeutic decision-making, based on the newest treatment. About Lucia M. Novak, MSN, ANP-BC. BC-ADMPresident and Owner, Diabetes Consulting Services, Rockville, MDDiabetes Expert, Diabetes & Endocrine Associates, Silver Spring, MDMs. Novak is a board-certified nurse practitioner in both Adult Health and Advanced Diabetes Management and has over 17 years of clinical, research and educational experience in diabetes mellitus. Ms. Novak has provided her expertise pertaining to diabetes as a Contributing Author for the Lippincott Manual of Nursing Practice for the last 4 editions and is also a Contributing Author for the 1st edition of Genomic Essentials for Graduate Level Nurses. Ms. Novak serves as an Associate Editor for Clinical Diabetes. Ms. Novak has been repeatedly recognized for her outstanding contributions as a clinician, researcher and educator. In 2015, she was designated Master Clinician for her proven leadership and clinical prowess, an accolade that placed her among the top 2% of the health care providers of the Walter Reed National Military Medical Center and is also a recipient of The DAISY Foundation Award for Extraordinary Nurses. Her nearly 28 years of nursing experience include active duty service as a Commissioned Officer of the United States Army Nurse Corps. This podcast episode  is supported by an  independent medical education grant from Novo Nordisk.  This activity is not certified for CME/CE credit.

In this episode, host Dr. Gregg Sherman and NACE expert faculty member, Dr. Mark Stolar,  discuss applying recent clinical study results and new CVD risk reduction data to daily clinical practice, including patient management strategies, treatment selection considerations, and current and emerging treatments.About Mark Stolar, MDMark Stolar, MD, is Associate Professor of Clinical Medicine, General Internal Medicine, and Geriatrics at Northwestern University Feinberg School of Medicine in Chicago, Illinois. Dr. Stolar received his medical degree from the University of Illinois, Chicago. He completed his fellowship in Endocrinology at the Northwestern University Medical School and his residency in internal medicine at Lutheran General Hospital. Dr. Stolar is board certified in endocrinology, diabetes, and metabolism, and internal medicine.Dr. Stolar's academic interests include diabetes, lipid disorders, and thyroid disease. A highly regarded speaker, he is actively involved in physician education in the area of diabetes and CV disease and has both written and presented in the US and internationally in those areas. He is currently president of the Endocrine Fellows Foundation and is actively involved in enhancing career opportunities for trainees in Endocrinology.About NACE http://naceonline.comMissionThe mission of NACE is to offer continuing education opportunities to provide learners in the fields of medicine, behavioral health, education, and related disciplines, with the most up-to-date, science-based information that will enable them to increase their knowledge, skills, confidence, and professional performance to ultimately benefit the public's health. VisionThe vision for NACE is to be recognized as the leader in primary care continuing education and to be known for a comprehensive suite of programs, which are tailored to the individual needs of practitioners and which emphasize innovation, outcomes, and clinical relevance.Commitment to ComplianceNACE received re-accreditation as an ACCME provider with Commendation in March 2014 and is committed to comply with the Criteria and Standards set forth by the ACCME, the ACCME's Content Validation Value Statement, and the AMA's Standards and Ethical Opinions to ensure that certified educational activities meet the highest standards.This educational activity is supported by an  independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.This activity is not certified for CME/CE credit. 

Joining Dr. Gregg Sherman  for this episode is Dr. James Underberg for a discussion about the impact of Hyperlipidemia management on Cardiovascular Risk Reduction. Click here to access NACE on-demand CME/CE courses on cardiovascular diseaseDr. Underberg is a Clinical Assistant Professor of Medicine at NYU Medical School & NYU Center for CV Prevention, Director of the Bellevue Hospital Lipid Clinic and Past President of the National Lipid Association. We very excited to spend a few minutes with Dr. Underberg to discuss current clinical guidelines, his insights about the evolving state of lipid management, and the impact of Hyperlipidemia management on Cardiovascular Risk Reduction.This activity is supported by educational funding provided by Amgen.This activity is not certified for CME/CE credit.

Thank you all for joining us on Holidaython 2016!!!! We are going to take this week off and re-hydrate & re-nutrate!!! Please enjoy this “Best Of” show!!! We are absolutely thrilled to talk with Jeff Sherman and Gregg Sherman, sons of Robert & Richard Sherman! We talk about what it took to make their documentary THE BOYS: THE SHERMAN BROTHERS’ STORY and their lives with their dads, Disney Legends!

Show Notes:  In this episode of The Tiara Talk Show, director and producer Gregg Sherman chats with host Tammy Tuckey about working with his cousin, Jeff Sherman, to direct & produce “The Boys: The Sherman Brothers’ Story” documentary, interviewing entertainment legends Julie Andrews & John Williams, his favorite Sherman Brothers song and more! Buy a copy of “The Boys: The Sherman Brothers’ Story” on Amazon here: http://amzn.com/B003TVTRY2 Are you looking to plan and book an upcoming Disney vacation? Contact The Tiara Talk Show’s official travel agent, James from MousePlanning.com by visiting http://bit.ly/QuoteMeDisney for a free quote! Be sure to… - Follow us on Twitter at @TiaraTalkShow: www.twitter.com/TiaraTalkShow - ‘Like’ our Facebook page: www.facebook.com/TheTiaraTalkShow - Follow us on our Tumblr page: thetiaratalkshow.tumblr.com - Follow us on our Google+ page: google.com/+TheTiaraTalkShow - Follow us on our Instagram page: instagram.com/thetiaratalkshow Want to give us your thoughts on this episode? Call us at 1-407-413-9390 and leave us a voicemail! Thanks for listening! “The Tiara Talk Show” is edited, created and hosted by Tammy Tuckey. The Tiara Talk Show is Copyright © 2013-2016 by Tammy Tuckey. All rights reserved.

We wrap up our interview with Jeff Sherman and Gregg Sherman, sons of Robert & Richard Sherman! We find out more about The Boys: The Sherman Brothers' Story, their lives growing up with Disney Legends and the time they met Walt Disney! (Due to the incredible volume of what Jeff & Gregg share, this is Part 2 of our 2 Part Episode 300.)  When listening in awe:  “Please Stand Clear Of The Doors”! Click here for your copy of The Boys! Thank you for downloading Episode 300 of ResortLoop.com! This episode of ResortLoop.com is brought to you by the Joffrey’s Coffee & Tea Company! Email or call in your own special open for the show! Voicemail: (414) WDW-LOOP

We are absolutely thrilled to talk with Jeff Sherman and Gregg Sherman, sons of Robert & Richard Sherman! We talk about what it took to make their documentary THE BOYS: THE SHERMAN BROTHERS' STORY and their lives with their dads, Disney Legends! (Due to the incredible volume of what Jeff & Gregg share, this is Part 1 of our 2 Part Episode 300.)  When listening in awe:  “Please Stand Clear Of The Doors”! Click here for your copy of The Boys! Thank you for downloading Episode 300 of ResortLoop.com! This episode of ResortLoop.com is brought to you by the Joffrey’s Coffee & Tea Company! Email or call in your own special open for the show! Voicemail: (414) WDW-LOOP  

01/05/11 - In this week's show, Pete Werner goes in alone as much of the team is sick with the flu. Pete rants about Disney coffee and the lack of resort specific merchandise and introduces everyone to the new Power of 10: Give Kids the World $1 million challenge. A DIS listener has a review of the Chefs Table experience at the Napa Rose at Disney's Grand Californian and DIS Senior Correspondent Dave Parfitt talks with Jeff and Gregg Sherman about The Boys: The Sherman Brothers Story. Call us toll free from within the U.S. at 877-310-9662 (outside U.S. call 407-574-5093).